Trial Profile
Phase I/II Pharmacokinetic Multi-Tumor Study of Subcutaneous Formulation of Nivolumab Monotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 11 Dec 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Nivolumab (Primary) ; Hyaluronidase
- Indications Carcinoma; Colorectal cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Urogenital cancer
- Focus Pharmacokinetics
- Acronyms CheckMate 8KX
- Sponsors Bristol-Myers Squibb
- 18 Nov 2022 Planned End Date changed from 14 Jul 2025 to 7 Mar 2025.
- 18 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 13 Sep 2022 Results of prespecified exploratory analysis presented at the 47th European Society for Medical Oncology Congress